United Kingdom (UK)
Recombinant monoclonal antibody to Clusterin. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 16B5.
UniProt Accession Number of Target Protein: P10909
Alternative Name(s) of Target: CLU; APOJ; CLI; KUB1; AAG4
Specificity: The antibody binds clusterin on the EMT-epitope.
Application Notes: The effect of the original format of the antibody was evaluated on lung metastasis in BALB/c mice with orthotopically implanted 4T1 cells. The antibody was able to significantly reduce lung metastasis (Lenferink et al., 2010; PMID: 19935703). A humanized version of the antibody was constructed. The humanized version of the antibody inhibited the EMT-inducing activity of clusterin on A549 NSCLC cells. Immunofluorescence was performed on A549 cells using this antibody to monitor E-cadherin expression. The combination of the humanized version of the antibody with erlotinib resulted in an enhanced anti-tumour effect (H1299 and H460 cells) (US9822170). AB-16B5 is a humanized IgG2 version of the antibody which specifically binds to tumour-associated clusterin and inhibits its activity. This antibody showed a good tumour inhibitory effect in in vivo application (Tremblay et al.; 2010). A phase I and phase II trial to assess safety and tolerability of AB-16B5 for the treatment of solid tumours was performed (Ferrario et al., 2017; NCT04364620).
Antibody first published in: PMID: